NeoRx Corporation (Seattle, WA) rep...
NeoRx Corporation (Seattle, WA) reports that Phase 1/2 studies of skeletal targeted radiotherapy with high-dose melphalan and main stock cell transplantation in enslaves with multiple myeloma demonstrated an overall reply rate of 64%, including a total response rate of 35%. Among the 29 make liables who achieved a complete reply the median duration of rejoinder to date is ...
|